title: Effects of ocular carteolol and timolol on plasma high-density lipoprotein cholesterol level.
abstract: Fifty-eight healthy, normolipidemic adult men participated in a prospective, masked, randomized crossover study designed to compare the effects of two topical nonselective beta-adrenergic antagonists, carteolol and timolol, on plasma high-density lipoprotein cholesterol levels. Two eight-week treatment periods were separated by an eight-week drug-free period. Carteolol 1.0% or timolol 0.5% was used, one drop twice daily, in both eyes without nasolacrimal occlusion. Fresh plasma was assayed for levels of total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglycerides, and apolipoproteins A-I and B-100. With indistinguishable effects on intraocular pressure, carteolol and timolol induced different (P = .013) decrements in high-density lipoprotein cholesterol levels. Carteolol treatment decreased high-density lipoprotein cholesterol levels by 3.3% (-0.04 mmol/l) and raised the ratio of total to high-density lipoprotein cholesterol levels by 4.0% (0.15 unit); timolol treatment decreased high-density lipoprotein cholesterol levels by 8.0% (-0.10 mmol/l) and raised the ratio of total to high-density lipoprotein cholesterol levels by 10.0% (0.37 unit). There was no differential drug effect on the other lipid variables measured. Ocular nonselective beta-adrenergic antagonist therapy can produce clinically relevant decrements in high-density lipoprotein cholesterol levels in healthy men.
authors.affiliation: Department of Ophthalmology, Duke University Medical Center, Durham, North Carolina.
authors.forename: S F
authors.initials: SF
authors.lastname: Freedman
authors.forename: N J
authors.initials: NJ
authors.lastname: Freedman
authors.forename: M B
authors.initials: MB
authors.lastname: Shields
authors.forename: B
authors.initials: B
authors.lastname: Lobaugh
authors.forename: G P
authors.initials: GP
authors.lastname: Samsa
authors.forename: E U
authors.initials: EU
authors.lastname: Keates
authors.forename: A
authors.initials: A
authors.lastname: Ollie
mesh_terms: D000287:Administration, Topical; D000328:Adult; D002354:Carteolol / Q000008:administration & dosage / Q000494:pharmacology*; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000097:blood*; D004311:Double-Blind Method; D005123:Eye / Q000187:drug effects; D006801:Humans; D007429:Intraocular Pressure; D008055:Lipids / Q000097:blood; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions; D011446:Prospective Studies; D013999:Timolol / Q000008:administration & dosage / Q000494:pharmacology*
chemical_list: D008076:Cholesterol, HDL; D008055:Lipids; D009883:Ophthalmic Solutions; D013999:Timolol; D002354:Carteolol; D002784:Cholesterol